MT-2 (Melanotan II) Research: Pan-Melanocortin Receptor Pharmacology

MT-2 (Melanotan II) is a synthetic cyclic heptapeptide analogue of alpha-MSH developed through structure-activity relationship optimisation of the native 13 amino acid linear alpha-MSH sequence. Unlike MT-1 (linear, MC1R-selective) and PT-141 (cyclic, primarily MC3R/MC4R), MT-2 activates the full range of melanocortin receptors — MC1R, MC3R, MC4R, and MC5R — making it the pan-MCR reference agonist in melanocortin receptor research.

Structural Innovation: The Cyclic Lactam

MT-2's 7-residue cyclic structure (Ac-Nle-cyclo(Asp-His-D-Phe-Arg-Trp-Lys)-OH) is created by a lactam bond between Asp2 and Lys7. This cyclisation dramatically increases MC receptor affinity compared to linear analogues by pre-organising the His-D-Phe-Arg-Trp pharmacophore in the receptor-binding conformation. The cyclic structure also provides resistance to proteolytic degradation.

The N-terminal Nle (norleucine) residue — outside the cyclic ring — replaces Met4 from native alpha-MSH (and is the same Nle substitution used in MT-1), providing oxidative stability without methionine vulnerability.

Melanocortin Receptor Subtype Coverage

MC4R agonism by MT-2 connects melanocortin signalling to CNS energy homeostasis, appetite regulation, and sexual function research — areas where MC1R-selective MT-1 has no activity. MC3R, expressed in hypothalamic neurons, adipose tissue, and macrophages, adds another dimension beyond MC1R/MC4R pharmacology.

Relationship to PT-141

PT-141 (Bremelanotide) was developed by removing the C-terminal hydroxyl group of MT-2, converting the alcohol to a free carboxylic acid. This structural change produces a compound with similar cyclic geometry but modified receptor subtype balance and improved CNS penetration. The historical relationship (MT-2 → PT-141) makes comparative MT-2 versus PT-141 research important for understanding which structural element is responsible for the pharmacological differences between the two compounds.

Published Research References

MC4R and Energy Homeostasis Research

MT-2's activity at MC4R places it at the intersection of melanocortin pharmacology and energy balance research. MC4R in the hypothalamic paraventricular nucleus (PVN) and arcuate nucleus is the primary target of alpha-MSH released from POMC neurons — the endogenous anorexigenic signal that opposes the orexigenic AgRP/NPY system.

Published research using MC4R-selective tools has established that MC4R activation suppresses food intake and increases energy expenditure through autonomic nervous system outflow. MT-2, as a pan-MCR agonist with high MC4R activity, is studied in these energy balance contexts alongside more selective tools.

Relevant research applications:

• MC4R functional assays (cAMP, beta-arrestin recruitment, receptor internalisation)
• Hypothalamic slice electrophysiology examining POMC and AgRP neuron responses
• Comparative pharmacology of MC4R agonism versus MC1R agonism on inflammatory markers (using MT-2 versus MT-1)
• Appetite-related signalling research in hypothalamic cell models

Cyclic vs Linear Pharmacophore Research

The structural comparison between linear MT-1 and cyclic MT-2 — with the same core pharmacophore but dramatically different receptor selectivity profiles — is itself an important research question in MCR structure-activity relationship studies. The conformational constraint imposed by the Asp2-Lys7 lactam bridge in MT-2 positions the His-D-Phe-Arg-Trp pharmacophore in a geometry that enables high-affinity binding across all MCR subtypes, while the flexible linear conformation of MT-1's 13 residues naturally adopts a geometry more selective for MC1R. Running parallel binding and functional assays with both MT-1 and MT-2 at equivalent nominal concentrations allows researchers to characterise the pharmacophore geometry requirements of individual MCR subtypes.

For laboratory and analytical research purposes only. Not for human or veterinary use.

Related: MT-1 | PT-141 | KPV
View MT-2 product and buy →

Cyclic Peptide Design: Conformational Constraint and Receptor Pharmacology

The Asp2-Lys7 lactam bridge in MT-2 exemplifies a general principle in peptide medicinal chemistry: conformational constraint through cyclisation improves receptor affinity by pre-organising the pharmacophore in the receptor-bound conformation, reducing the entropic cost of binding.

Linear alpha-MSH (the 13aa parent) must adopt a specific conformation when binding MCRs — the flexible linear peptide samples many conformations in solution, and only the receptor-binding conformation contributes to productive binding. The conformational energy cost of binding (entropic penalty) is substantial. MT-2's cyclic structure limits the conformational freedom of the His-D-Phe-Arg-Trp pharmacophore to geometries compatible with receptor binding, reducing this entropic cost and thereby increasing apparent binding affinity.

Structure-activity relationship (SAR) research comparing MT-2 with: (1) linear analogues of the same sequence (without the lactam bridge), (2) MT-1 (linear 13aa analogue), and (3) PT-141 (same cyclic structure with C-terminal modification) allows systematic characterisation of how conformational constraint affects MCR binding affinity, selectivity, and functional activity. Such SAR studies are the basis for rational design of next-generation melanocortin research tools.

MC4R and Obesity Research: The AgRP/MT-2 Balance

The well-established role of MC4R in energy homeostasis research creates an important context for MT-2's pharmacology in metabolic research. The MC4R anorexigenic pathway is mediated by: POMC neurons in the arcuate nucleus releasing alpha-MSH → MC4R activation in PVN → reduced food intake and increased energy expenditure. The opposing orexigenic pathway: AgRP neurons releasing AgRP → MC4R antagonism → increased appetite. MT-2's high MC4R agonist activity means it pharmacologically mimics the POMC pathway regardless of the endogenous AgRP/alpha-MSH balance.

Published research using MT-2 in metabolic biology models has examined: MC4R-mediated suppression of hypothalamic AgRP and NPY gene expression (measuring mRNA by qPCR in dissected arcuate nucleus), hypothalamic PVN neuron electrophysiology (whole-cell patch-clamp in hypothalamic slices), and comparative pharmacology with selective MC4R agonists to distinguish MC4R-specific from MC1R/MC3R/MC5R-mediated metabolic effects. MT-2 serves as the pan-MCR positive control in these studies, with MT-1 (MC1R selective) and PT-141 (MC4R/MC3R primary) providing the selectivity comparators.

Frequently Asked Questions

How did the structure of MT-2 lead to the development of PT-141?
PT-141 (Bremelanotide) was developed by removing the C-terminal hydroxyl group from the MT-2 structure, converting the alcohol to the free carboxylic acid (the Lys7 C-terminus becomes a free COOH rather than a free OH). This structural change was made to explore whether the hydroxyl group contributed to MT-2's peripheral cardiovascular side effects observed in early research. PT-141 showed improved CNS penetration and a CNS-focused pharmacological profile compared to MT-2, while maintaining MC4R agonism. The lactam ring structure (Asp2-Lys7 bridge) is preserved identically in PT-141 — the conformational constraint that makes both compounds high-affinity MCR agonists.

What assays confirm MT-2's pan-MCR activity across all five receptor subtypes?
Standard confirmation uses parallel functional assays in cells expressing individual MCR subtypes: CHO or HEK293 cells stably expressing human MC1R, MC2R, MC3R, MC4R, or MC5R individually, with cAMP accumulation as the primary readout (all MCRs couple to Gs/adenylyl cyclase). EC50 values at each receptor confirm pan-agonist activity profile and relative potency at each subtype. For MC2R specifically (ACTH receptor, expressed in adrenal glands), note that MC2R requires the melanocortin 2 receptor accessory protein MRAP for functional expression in heterologous systems — MRAP co-expression is essential for MC2R functional assays but not required for MC1R/MC3R/MC4R/MC5R.

Browse all Signal Labs research peptides | Peptide storage guide | Reconstitution guide